Immuneering Corporation · NASDAQ:IMRX
Immuneering — Investor Presentation (November 2025)
30 slides from Immuneering's investor presentation, November 2025
Slide 1: Keeping Cancer Patients Alive and Helping Them Thrive
Keeping Cancer Patients Alive and Helping Them Thrive November 2025 1 2025 Presentation
Slide 2: Forward-Looking Statements and Other Disclaimers
. FORWARD-LOOKING STATEMENTS AND OTHER DISCLAIMERS This presentation contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be con
Slide 3: Immuneering: Improving Durability and Tolerability of Cancer Treatment
Immuneering Improving the Durability and Tolerability of Cancer Treatment with Innovative Deep Cyclic Inhibitors ❖ Extraordinary overall survival and favorable tolerability in ongoing Phase 2a study of atebimetinib + mGnP in first-line pancreatic cancer patients, potential for best-in-class profile
Slide 4: Extraordinary Overall Survival Observed
Extraordinary Overall Survival (OS) Observed at 9 Months in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP OS, N=34 94% 86% 6 mo. 9 mo. OS Probability Atebimetinib + mGnP (320 mg atebi; N=34) 9-month OS 86% [66, 94] As of the August 26, 2025 data cutoff, the median follow-up for overal
Slide 5: Extraordinary Overall Survival vs Standard of Care
Extraordinary Overall Survival (OS) Observed at 9 Months in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP OS, N=34 94% 86% 9-month OS atebimetinib Standard of Care +27% + mGnP 86% [66, 94] Ph3 MPACT IMRX +39% Standard of ~47% OS Probability (Gem/nab-Pac) Phase 2a (atebi + mGnP) Care G
Slide 6: Overall Survival vs Benchmark Phase 3 Studies
Extraordinary Overall Survival (OS) Observed at 9 Months in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP OS, N=34 — Ph2a IMRX (atebimetinib + mGnP) Atebimetinib + mGnP OS Probability (320 mg atebi-; N=34) 9-month OS 86% [66, 94] — Ph3 NAPOLI-3 (NALIRIFOX) — Ph3 PRODIGE (FOLFIRINOX) A
Slide 7: Progression-Free Survival Supports Extraordinary Overall Survival
Progression-Free Survival (PFS) Supports Extraordinary Overall Survival in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP PFS, N=34 Atebimetinib + mGnP (320 mg atebi-; N=34) 9-month PFS 53% [31, 71] 70% As of the August 26, 2025 data cutoff, the median PFS Probability 6 mo. follow-up f
Slide 8: Progression-Free Survival vs Standard of Care
Progression-Free Survival (PFS) Supports Extraordinary Overall Survival in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP PFS, N=34 9-month PFS atebimetinib 70% + mGnP 53% [31, 71] Standard of Care GnP ~29% +26% 53% 6-month PFS atebimetinib 44% +24% + mGnP 70% [49, 83] 6 mo. Standard o
Slide 9: Progression-Free Survival vs Benchmark Studies
Progression-Free Survival (PFS) Supports Extraordinary Overall Survival in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP PFS, N=34 Atebimetinib + mGnP — Ph2a IMRX (atebimetinib + mGnP) (320 mg atebi-; N=34) — Ph3 NAPOLI-3 (NALIRIFOX) — Ph3 PRODIGE (FOLFIRINOX) — Ph3 MPACT (Gem/nab-Pac
Slide 10: Overall Response Rate and Disease Control Rate
Overall Response Rate (ORR) and Disease Control Rate (DCR) Support Extraordinary Overall Survival in First-Line Pancreatic Cancer Atebimetinib + mGnP Best % Change in RECIST SLD Overall Response (ORR) & Disease Control (DCR) Rates Atebimetinib + mGnP Ph 2a 1L PDAC 1 ORR 39% (14/36) DCR 81% (29/36) P
Slide 11: Deepening Tumor Responses Over Time Observed
Deepening Tumor Responses Over Time Observed Atebimetinib (320 mg QD) + mGnP RECIST SLD (% change) = ref ractory to treatment combination (N=3, on treatment = 0) Months = stabilized with eventual or potential escape (N=6, on treatment = 1) (from screening scan) = stabilized with durable or deepening
Slide 12: Favorable Tolerability Profile
Favorable Tolerability Profile in First-Line Pancreatic Cancer Safety Data for Pivotal Trials and for Atebimetinib + mGnP in 1L PDAC Gem/nab-Pac FOLFIRINOX NALIRIFOX Atebimetinib + mGnP PIVOTAL STUDY (1 MPACT; N=431) (2 PRODIGE/ACCORD 11; N=171) (3 NAPOLI 3; N=383) (320 mg atebi-; N=34) Grade ≥ 3 Gr
Slide 13: Atebimetinib + mGnP Evaluated in Older Patient Population
Atebimetinib + mGnP Evaluated in Older Patient Population IMRX Ph2a (320 mg) MPACT PRODIGE/ACCORD 11 NAPOLI 3 Characteristic Atebimetinib + mGnP Gem/nab-Pac FOLFIRINOX NALIRIFOX Trial Phase Phase 2a Phase 3 Phase 2/3 Phase 3 Metastatic PDAC Patient Population Metastatic PDAC Metastatic PDAC Metastat
Slide 14: Global Randomized Pivotal Trial Plan
Global Randomized Pivotal Trial Plan: Designed to Demonstrate Best-in-Class Profile in 1L PDAC Planned Patient Population: First-line (1L) metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Primary Endpoint Atebimetinib + mGnP1 OS (N=180) • First line (1L) PDAC Secondary Endpoints R • Metastatic set
Slide 15: Striking Outcomes in Case Studies from Additional Settings
Atebimetinib Delivers Striking Outcomes in Case Studies from Additional Settings Atebimetinib + mGnP1 First Line: TOP PRIORITY Phase 2 Atebimetinib + mFFX2 First Line Case Studies Atebimetinib Phase 1 Third Line Case Study • Mechanistic rationale supports synergy across standard 1L PDAC chemotherapy
Slide 16: Atebimetinib + mFFX Case Study: Complete Resolution of Tumor Lesion
Atebimetinib + mFFX Case Study: Observed Durability and Tolerability with Complete Resolution of Tumor Lesion Ongoing Phase 2 Case Study Atebimetinib + mFFX (1L PDAC; Phase 2) (1L Metastatic PDAC) RECIST SLD (% change) • 1st Line (1L): Atebi + mFFX (BOR = uCR) * -81.8% -54.5% -100% 71-year-old femal
Slide 17: Curative-Intent Whipple After Deep Tumor Response
Curative-Intent Whipple After Deep Pancreatic Tumor Response to Atebimetinib + mFFX in 1L PDAC Ongoing Phase 2 Case Study Atebimetinib + mFFX (1L PDAC; Phase 2) (1L Biopsy-Confirmed Metastatic PDAC) RECIST SLD (% change) • 1st Line (1L): Atebi + mFFX (BOR = uPR → Whipple) * o 61-year-old female -56%
Slide 18: Atebimetinib Monotherapy Case Study: Resolution of Bone Lesion
Atebimetinib Monotherapy Case Study Showed Durability and Tolerability with Complete Resolution of Bone Lesion Ongoing Phase 1 Case Study Atebimetinib Monotherapy (3L PDAC; Phase 1) (3L Metastatic PDAC) RECIST SLD • 1st Line (1L): FOLFIRINOX (BOR = PD) (% change) • 2nd Line (2L): Gem/Cis/nab-Pac (BO
Slide 19: How does atebimetinib work?
Changing the paradigm for targeted therapy, to improve durability and tolerability. How does atebimetinib work? 19 2025 Presentation
Slide 20: Atebimetinib goal: achieve durability by outpacing cancer
Atebimetinib goal: achieve durability by outpacing cancer Our drug candidates are Most therapies are designed designed for deep cyclic for sustained inhibition, inhibition, driving cancer to adapt and pulsing faster than cancer develop resistance; tumors can adapt; tumors shrink shrink quickly but t
Slide 21: Atebimetinib goal: achieve tolerability by outpacing cancer
Atebimetinib goal: achieve tolerability by outpacing cancer proliferative signaling Healthy Cells: Transient Signaling Time → proliferative signaling Cancer Cells: Sustained Signaling Time → Sustained Inhibition Deep Cyclic Inhibition (DCI) proliferative proliferative signaling signaling IC50 ≥ IC90
Slide 22: Atebimetinib targets MEK in the MAPK pathway
Atebimetinib targets MEK in the MAPK pathway, designed to outpace cancer with durability and tolerability “the MAPK pathway is altered RAS or inappropriately activated in a majority of cancers” BRAF CRAF Approved MEK Atebimetinib P Inhibitors MEK P DCI MEKi Our initial focus for atebimetinib Chronic
Slide 23: Phase 1 Monotherapy Activity and Molecular Rationale for Combination
Phase 1: Atebimetinib monotherapy showed activity, durability, and tolerability Phase 2a: Evaluating atebimetinib + mGnP in first line pancreatic cancer Molecular rationale for the combination MIA PaCa-2: Human PDAC Xenograft Copy of 125_Fig-Data: TV (mm3) - ALL groups: IMM-1-104 at 125 mpk BID Phas
Slide 24: Targeting the MAPK Pathway: Broad Relevance in Most Cancers
Targeting the MAPK Pathway: Broad Relevance in Most Cancers, Expansive Opportunity Pancreatic Cancer Lung Cancer Colorectal Cancer Melanoma …and many more 24 2025 Presentation
Slide 25: Emergent Atebimetinib Monotherapy and Combinations
Emergent Atebimetinib Monotherapy and Combinations Vertical Immune Modifying Orthogonal MoA Monotherapy Combinations Combinations Combinations Pulsatile Selective Dual-targeting of Non-overlapping MAPK Pathway Vertical Drug Tumor & Immune Mechanism of Action Inhibition Combinations System Combinatio
Slide 26: Clear Expected Milestones Ahead
Extraordinary Overall Survival (OS) Observed at 9 Months in First-Line Pancreatic Cancer With Clear Expected Milestones Ahead Atebimetinib (320 mg QD) + mGnP OS, N=34 Expected Expected 94% Timing Milestones 86% 6 mo. • Feedback from regulatory Q4 2025 agencies; continue preparations 9 mo. OS Probabi
Slide 27: Immuneering: Improving Durability and Tolerability of Cancer Treatment
Immuneering Improving the Durability and Tolerability of Cancer Treatment with Innovative Deep Cyclic Inhibitors ❖ Extraordinary overall survival and favorable tolerability in ongoing Phase 2a study of atebimetinib + mGnP in first-line pancreatic cancer patients, potential for best-in-class profile
Slide 28: Appendix
Appendix 28 2025 Presentation
Slide 29: Extraordinary Overall Survival Observed
Extraordinary Overall Survival (OS) Observed at 9 Months in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP OS, N=34 Atebimetinib + mGnP (320 mg atebi-; N=34) OS Probability 9-month OS 86% [66, 94] As of the August 26 data cutoff, the median follow-up for overall survival (OS) was 9.0 m
Slide 30: Progression-Free Survival Supports Extraordinary Overall Survival
Progression-Free Survival (PFS) Supports Extraordinary Overall Survival in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP PFS, N=34 Atebimetinib + mGnP (320 mg atebi-; N=34) PFS Probability 9-month PFS 53% [31, 71] As of the August 26 data cutoff, the median follow-up for overall survi